关键词: 疼痛, 癌, 非小细胞肺, 瑞舒伐他汀, 盐酸羟考酮缓释片, 增效作用, 安全性

Abstract: Objective　To investigate the synergy and security of rosuvastatin with oxycodone hydrochloride controlled release tablets in treating advanced non-small cell lung cancer patients’ cancer pain.Methods　From January 2014 to January 2015,we enrolled 160 patients with advanced non-small cell lung cancer who accorded with the inclusion criteria from the Oncology Department of Yishui Central Hospital of Linyi.These patients were assigned into treatment group and control group by random number table method,with 80 patients in each group.On the basis of conventional chemotherapy,control group was given oxycodone hydrochloride controlled release tablets,and treatment group was given oxycodone hydrochloride controlled release tablets plus rosuvastatin calcium tablets for analgesia.Before treatment and one week after treatment,the levels of IL-6 and TNF-α were detected.One week after treatment,the effective doses of the two groups were recorded;the times of breakthrough pain,NRS score and the effective rate of cancer pain treatment of the two groups were recorded when they were given the average effective dose of oxycodone hydrochloride controlled release tablets of the treatment group;the incidence rates of adverse reaction （constipation,nausea and vomiting,liver function damage and respiratory depression） of the two groups were recorded when the two groups were given effective doses of oxycodone hydrochloride controlled release tablets respectively.Results　Before treatment,the two groups were not significantly different in the levels of IL-6 and TNF-α （P>0.05）;after treatment,treatment group was lower than control group in the levels of IL-6 and TNF-α （P<0.05）.Treatment group had lower IL-6 and TNF-α levels after treatment than those before treatment （P<0.05）.Treatment group was lower than control group in effective dosage,the times of breakthrough pain and NRS score （P<0.05）.The effective rate of cancer pain treatment of treatment group was 97.5% （78/80）,higher than that of control group which was 80.0% （64/80） （χ2=12.269,P<0.01）.Treatment group was lower than control group in the incidence of constipation （P<0.05）;the two groups were not significantly different in the incidence rates of nausea and vomiting,liver function damage and respiratory depression （P>0.05）.Conclusion　Rosuvastatin plus oxycodone hydrochloride controlled release tablets has synergistic effect in the treatment of patients with advanced non-small cell lung cancer pain,and the incidence rates of adverse reactions can be lowered by reducing the dosage of oxycodone hydrochloride controlled release tablets.

Key words: Pain, Carcinoma,non-small-scell lung, Rosuvastatin, Oxycodone hydrochloride controlled release tablets, Synergistic effect, Safety